The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Q2 2025 Results Conference Call February 6, 2025 10:30 AM ETCompany ParticipantsKellie Smythe - Senior Director ...
There are important distinctions in cancer diagnoses and deaths among different regions of Appalachia, with certain areas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback